Skip to main content
Fig. 6 | Arthritis Research & Therapy

Fig. 6

From: Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis

Fig. 6

TJC in association with JSN score by secukinumab treatment and visits. This analysis is based only on FUTURE 5, since FUTURE 1 deals with unapproved doses. Each panel depicts a scatterplot of joint tender counts versus JSN vdH-mTSS scores at three time points (Weeks 0, 16, and 52) for each secukinumab dose. The loess smoothed curves depict the overall pattern of TJC and JSN at each time point, and thus the overall improvement in terms of joint counts over time due to secukinumab treatment. However, patients with high radiographical JSN scores tend to have incomplete recovery even after 52 weeks of treatment. JSN, joint space narrowing; MDA, minimal disease activity; NL, no loading doses; TJC, tender joint count

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us